Athersys Inc (ATHXQ)

OTCMKTS: ATHXQ · Delayed Price · USD
0.00
0.00 (0.00%)
No quote available
Market Cap 95.22K
Revenue (ttm) 145,000
Net Income (ttm) -47.41M
Shares Out 20.70M
EPS (ttm) -2.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ATHXQ

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrom... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 24
Stock Exchange OTCMKTS
Ticker Symbol ATHXQ
Full Company Profile

Financial Performance

In 2022, Athersys's revenue was $5.33 million, a decrease of -3.43% compared to the previous year's $5.51 million. Losses were -$72.53 million, -16.58% less than in 2021.

Financial Statements

News

Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results fo...

6 months ago - Business Wire

Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indica...

7 months ago - Business Wire

Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the inde...

8 months ago - Business Wire

Athersys Licenses its Animal Health Assets to Ardent Animal Health

CLEVELAND & LEXINGTON, Ky.--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Mu...

8 months ago - Business Wire

Athersys Director Jane Wasman Appointed Board Chair

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Direct...

8 months ago - Business Wire

Grant Awarded to Newcastle University to Research Athersys' MultiStem® in Machine Perfusion Prior to Kidney Transplantation

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samu...

9 months ago - Business Wire

Athersys, Inc. Announces Pricing of $3.5 Million Public Offering

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), today announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock (or common stock equivalent...

10 months ago - Business Wire

Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results...

10 months ago - Business Wire

Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema...

10 months ago - Business Wire

Athersys to Host Business Update Conference Call on August 9th

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will...

10 months ago - Business Wire

Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys' MultiStem® Following Hemorrhagic Trauma

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollmen...

1 year ago - Business Wire

Athersys Restructures Debt with Supplier

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications announced it has restructure...

1 year ago - Business Wire

Athersys Reports First Quarter 2023 Financial Results and Business Highlights

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15...

1 year ago - Business Wire

Athersys to Participate in Three Upcoming Conferences

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today its partici...

1 year ago - Business Wire

Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their parti...

1 year ago - Business Wire

Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their parti...

1 year ago - Business Wire

Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it has closed its previously announced offering to sell 3,685,000 shares (the “Shares”) of the Company's common stock (or...

1 year ago - Business Wire

Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the “Shares”) of the Company's c...

1 year ago - Business Wire

Athersys to Host Business Update Conference Call on April 20th

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will...

1 year ago - Business Wire

Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) today announced financial results for the three and 12 months ended December 31, 2022, and provided a business update.

1 year ago - Business Wire

Athersys Announces Successful Type B Meeting with the FDA

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced planned amend...

1 year ago - Business Wire

Athersys Expands IP Protection with First New Patent for SIFU® Technology

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that th...

1 year ago - Business Wire

Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that th...

1 year ago - Business Wire

Athersys to Host Business Update Conference Call on February 14th

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it wi...

1 year ago - Business Wire

Athersys to Participate in International Stroke Conference and BioProcess International

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its p...

1 year ago - Business Wire